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Background: Absorbable metal scaffolds (AMS) are attractive as after absorption they
only leave behind the healed, natural vessel without permanent implant, allowing
restoration of vasoreactivity with the potential for vessel remodelling. Magnesium is
an essential element of the human body, thus Magnesium is considered as a potential
alloy for absorption. To overcome the limitations associated with the first generation
of a bare AMS, a Drug (Paclitaxel) Eluting Absorbable Magnesium Scaffold was
developed (DREAMS).
Methods: Between July and December 2010, 46 subjects were enrolled in the first-in-
man BIOSOLVE-I study, assigned to two different cohorts with different follow-up
schedules. Clinical follow-up for both cohorts are at 1, 6, 12, 24 and 36 months,
angiographic follow-up for cohort 1 at 6 months and for cohort 2 at 12 months.
Angiographic assessments are evaluated by an independent core laboratory. The
primary endpoint is Target Lesion Failure (TLF), defined as cardiac death, target vessel
myocardial infarction and clinically driven target lesion failure, at 6 months for cohort
1 and at 12 month for cohort 2.
Results: Of the 46 subjects 34 were male and 12 were female subjects with a mean
age of 65.3 ± 9.7 years ranging from 42 to 80 years. Hyperlipidemia (89%),
hypertension (87%) and history of myocardial infarction (33%) were the major medical
risk factors. Type A (45%), Type B1 (51%) and Type B2 (4%) lesions were treated
with a 3.25 / 16 mm (49%) or a 3.5 / 16 mm (51%) DREAMS. Acute results on all 46
patients enrolled in the BIOSOLVE-I study demonstrate 100% device and 100%
procedure success as well as excellent safety results. Up to six months no cardiac death,
no myocardial infarction and no scaffold thrombosis occurred in any of the subjects.
Target Lesion Failure rate is comparable to other first in man studies.
Conclusion: DREAMS is a safe drug eluting absorbable metal scaffold with a TLF
Rate which is comparable with conventional permanent drug eluting stents in first-in-
man trials. Six- month angiographic assessment is ongoing and QCA results will be
available upon presentation.
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Materials and Science Engineering, Nanyang Technological University, Singapore,
Singapore
Background: Drug delivery balloons (DDBs) are a new class of medical devices
developed to address the growing US$7B atherosclerosis market. DDBs are designed
to simultaneously open blocked blood vessels while delivering drugs to prevent
restenosis. While clinical results are promising, the drug coating used on current DDBs
is not optimal, resulting in significant drug loss during the procedure, inaccurate dosing,
and poorly defined pharmacokinetics. This has raised concerns within the clinical and
regulatory community regarding the safety and long term efficacy of DDBs.
Methods: A pressure-sensitive bioadhesive coating embedded with drug eluting
nanoparticles has been developed. The robust bioadhesive coating is designed to
transfer upon PTCA balloon inflation. When the balloon is subsequently deflated and
removed, the bioadhesive coating will remain attached to the vessel wall, after which
the tissue-embedded nanoparticles will slowly deliver their therapeutic payload over a
1-4 week period. The bioadhesive will itself also dissolve completely in this time.
Results: The pressure-sensitive bioadhesive coating was evaluated for nanoparticle
penetration, pharmacokinetics, and tissue cytotoxicity in a ex vivo swine artery
bioreactor. Nanoparticle penetration, with the help of the bioadhesive, displayed drug
infiltration greater than >400 microns into the swine aorta artery. Optimized
nanoparticle/bioadhesive films transferred with a high degree of reproducibility, with
less than 1% of the film remaining on the PTCA balloon after inflation.
Conclusion: Drug delivery balloons incorporating a pressure-sensitive bioadhesive
embedded with drug eluting nanoparticles is promising towards treatment of restenosis.
Further development of bioadhesive films is warranted toward a potential therapy in
cardiovascular disease, and other vascular pathologies.
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Background: Permanent polymeric drug-eluting stents (DES) demonstrate some
coronary arterial luminal loss late after implantation (“late catch-up”). In contrast, after
implantation of a bioresorbable everolimus-eluting scaffold (ABSORB, Abbott
Vascular, CA) in the small 30 patient ABSORB Cohort A trial there was luminal
enlargement between 6 months and 2 year follow-up. Cohort B of the ABSORB trial
evaluates the modified ABSORB device that is similar in many aspects but has greater
and longer lasting radial strength while resorbing sufficiently by 12 months to permit
vasomotion indicating that the vessel is no longer caged. If there is absence of “late
catch-up” or even luminal enlargement between 6 months and 2 years for the Cohort
B ABSORB scaffold, this could be an important differentiation from metallic DES.
Methods: The ABSORB Cohort B 101 patients were divided into 2 groups on the basis
of angiographic follow-up timing: Group B1 (45 patients) having this at 6 months and
2 years and Group B2 (56 patients) having this at 1 and 3 years.
Results: Clinical results in all 101 patients showed an ID-MACE rate of 6.9% with no
scaffold thromboses. Angiographic results at 6 months (B1) and 1 year (B2) showed
comparable ABSORB LL compared with XIENCE V Everolimus Eluting Coronary
Stent System in the SPIRIT FIRST First-In-Man trial (0.18mm vs. 0.10mm and
0.27mm vs. 0.23mm, see figure below). The 2-year clinical and angiographic results
for Group B1 from the ABSORB Cohort B trial will be presented.
Conclusion: One year clinical outcome of ABSORB Cohort B showed the scaffold to
be safe; two year follow-up clinical and angiographic data analysis is pending.
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Background: Percutaneous coronary interventions (PCI) are increasingly performed
worldwide to treat patients with coronary artery disease. However, studies regarding
the influence of ethnicity on clinical outcomes after PCI are scarce. In our current
analysis, we evaluate the differences in baseline clinical, angiographic and procedural
characteristics, and 12-month clinical outcomes in patients undergoing non-urgent PCI
in Western Europe and in Asia.
Methods: We analysed all patients enrolled in the worldwide e-HEALING registry
living in Western Europe and Asia. All patients were treated with at least one Genous
stent. The main study outcome was target vessel failure (TVF) at 12-months, defined
as the composite of death or MI and target vessel revascularization.
Results: All 3504 patients, 2873 living in Western Europe and 731 living in Asia, were
assessed in the current analysis. Nearly all baseline clinical and angiographic
characteristics differed significantly between both groups. TVF at 12 months occurred
in 11.4% of the Western Europe patients and in 5.6% of the Asian patients (p<0.01).
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Conclusion: We conclude that differences exist in baseline, angiographic and
procedural characteristics, and 1-year clinical outcomes between Western-European
and Asian patients undergoing non-urgent PCI. Our results indicate that reports from
worldwide performed studies should include both overall and regional subgroups
outcomes.
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Background: The safety and performance of the ABSORB™ Bioresorbable Vascular
Scaffold (BVS) System (Abbott Vascular, Santa Clara, CA) has been previously
established in 131 patients from Cohort A and Cohort B of the First-in-Man ABSORB
trial. Following this trial, ABSORB EXTEND was initiated as a global continued
access study (outside of the US) to expand experience with the ABSORB BVS to
patients with increased lesion complexity. This includes patients treated for longer
coronary lesions than those in the ABSORB trial using either longer scaffold lengths
or planned overlap of the ABSORB BVS.
Methods: ABSORB EXTEND is a prospective, single-arm, open-label clinical study
that is planning to enroll up to 1,000 subjects at up to 100 sites. Included are patients
with lesions ≤ 28 mm in length and reference vessel diameter of 2.0 - 3.3 mm (as
assessed by on-line QCA). Treatment of a maximum of two de novo native coronary
artery lesions, each in a different epicardial vessel, is permitted.
Results: Results out to 1 year have been presented in 101 patients from the ABSORB
Cohort B trial. At 6 months, the MACE rate was 5.0% (5/101), with no cardiac death
or scaffold thrombosis reported. These clinical results were sustained out to 12 months
in Cohort B with a MACE rate of 6.9% (7/101) reported at 12 months. Preliminary 6-
month data in the first 200 patients enrolled in ABSORB EXTEND will be available
for the first time in October 2011 and will provide additional data on the safety and
performance of the ABSORB BVS in a larger population of patients, including those
with longer lesions and two-vessel disease. Clinical composites and component end
points will be presented out to 6 months.
Conclusion: Clinical and angiographic outcomes from the First-in-Man ABSORB trial
have demonstrated the safety and efficacy of the ABSORB BVS in lesions ≤ 14 mm.
Preliminary outcomes in 200 patients at 6 months from ABSORB EXTEND will
provide further insight into the mid-term safety and efficacy of the ABSORB BVS in
patients with longer lesions.
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Predictors Of Adverse Cardiac Events after PCI With GENOUS EPC-Coated
Stents Compared To Drug Eluting Stents
Boris Rudenko, Anatoly Savchenko, Serdgey Tereshchenko, Olga Cherkavskaya
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Background: The purpose of our study is to analyze the long-term results of coronary
intervention with DES and EPC-capturing stents, and determine risk factors influencing
long-term adverse coronary events rate after usage of different types of stents.
Methods: 2362 patients were enrolled in the study. 316 patients underwent
percutaneous coronary interventions (PCI) with EPC capturing Genous stent, 2046
patients - with drug (sirolimus) eluting stents. The primary endpoint of the study was
the occurrence of MACE in two groups. The secondary endpoints were the rate of stent
thrombosis, stent restenosis, level of pnflammatory response after discontinuation of
dual antiplathelet therapy. In each group independent predictors of MACE were
determined.
Results: During second year of follow-up the incidence of MACE was 16% in DES
group and 14% - in Genous group. In Genous group more patients requred subsequent
revascularization procedures(12%)compared to DES group(4%).In DES group age,
renal insufficiency, diabetes mellitis,discontinuation of DAPT due to noncardiac
surgery were inedtifed as univariate predicrots. Discontinuation of DAPT was the
independent predictors of MACE in DES group. In Genous group age,diabetes mellitis,
long lesion were univariate predicrots, long lesions became the independent predictors
of MACE.In DES group in diabetic patients there was increase of C-protein level after
discontinuation of dual antiplathelet therapy. Patients after DES implantation and
noncardiac surgery had higher rate of stent thrombosis (18%) rate compared to patients
after Genous stents (0%).
Conclusion: Patients with clopidogrel withdrawal because of the non-cardiac surgery
have the worst outcome among SES-implanted patients.The discontinuation of
clopidogrel in diabetic patients with EPC-coated stents doesn’t cause increase in
markers of inflammation compared to SES stents. Long lesion is the independent
predictors of restenosis after EPC stent implantation and the length of stented surface
correlates strongly with in-stent lumen diameter late loss.
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Background: Delayed healing, stent thrombosis, late-catch-up and neo-atherosclerosis
are unfavorable late-term outcomes associated in part with permanent polymers of
current drug-eluting stents (DES). The MiStent DES (Micell Technologies, Durham,
NC), designed for improved safety while maintaining strong efficacy, is characterized
by use of crystalline sirolimus, drug release at a controlled, linear rate, coating off the
stent in 45-60 days with full absorption of the polymer by 90 days and a thin strut
(64um) cobalt-chromium stent.
Methods: The DESSOLVE I FIH clinical trial is a prospective, single-arm study at 5
sites evaluating the MiStent DES for preliminary safety and efficacy. Patients with
discrete de novo lesions (2.5-3.5 mm diameter and ≤20 mm length) in native coronary
arteries were enrolled. Following the MiStent DES placement, patients were evenly
assigned to 3 groups for follow-up imaging (angiography, IVUS and OCT) at 4-months,
6-months or 8-months to determine in-stent late lumen loss (LLL), vessel healing, and
stent coverage. Clinical safety was conducted for all 30 patients at 8-months.
Results: The initial 10 patients evaluated at 4-months demonstrated an in-stent LLL
of 0.01 ± 0.12 mm assessed by core laboratory quantitative angiography. Imaging with
OCT demonstrated thin, homogenous coverage with high rates of stent strut coverage
(70% of the patients having >90% strut coverage and 90% having >80% strut coverage)
with a low rate of stent strut malapposition. The IVUS findings supported minimal
neointimal hyperplasia with a neointimal obstruction of 5.2%. Clinical outcomes and
angiographic, OCT and IVUS analyses at 4, 6 and 8-months for the entire study cohort
will be presented.
Conclusion: The MiStent DES, developed with a predictably absorbed polymer
encompassing a new morphology of sirolimus, may address current DES concerns
B67JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/Bioabsorbable, Drug-Eluting, and Bare Metal Stent Studies
P
O
S
T
E
R
S
www.JACC.TCTAbstracts2011
